Rasha Aboelhassan shared on Linkedin:
”One of the best things we get from discussing experts is knowing how they see the future.
During today’s Pfizer/Med Escape Symposium, I was excited about their mapping of future plans for HER2-positive breast cancer patients:
There are several changes coming that could change the guidelines.”
Source: Rasha Aboelhassan/Linkedin
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.
